These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7903511)

  • 21. [Acute inpatient treatment of manias. Effects of independent variables on neuroleptic dosage and length of stay].
    Adler L; Ulrich M; Lehmann K; Nordeck I; Langer C; Thomas RS; Hajak G; Koller M
    Nervenarzt; 1996 Mar; 67(3):235-43. PubMed ID: 8901282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Complications observed during use of lithium salt-neuroleptic combinations; comparative study of clinical evolution, EEG and pharmacokinetics].
    Granier F; Girard M; Loustalan JM; Thomas J; Escande M
    Ann Med Psychol (Paris); 1983; 141(8):891-908. PubMed ID: 6141759
    [No Abstract]   [Full Text] [Related]  

  • 23. [Has drug treatment of manic disorders changed in clinical routine practice? Retrospective analysis of treatment modalities and results in a university psychiatric clinic].
    Reetz-Kokott U; Müller-Oerlinghausen B
    Nervenarzt; 1996 Mar; 67(3):229-34. PubMed ID: 8901281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials.
    Suppes T; Vieta E; Gustafsson U; Ekholm B
    Depress Anxiety; 2013 Nov; 30(11):1089-98. PubMed ID: 23761037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study.
    Zarate CA; Tohen M
    J Clin Psychiatry; 2000 Jan; 61(1):33-8. PubMed ID: 10695644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
    Prescrire Int; 2005 Aug; 14(78):140-2. PubMed ID: 16106596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Persistent neurological syndrome after treatment with lithium salts. Toxicity of the lithium-neuroleptic combination?].
    Habib M; Khalil R; le Pensec-Bertrand D; Ali-Cherif A; Bongrand MC; Crevat A
    Rev Neurol (Paris); 1986; 142(1):61-4. PubMed ID: 2871617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year rehospitalization rates of patients with first-episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics.
    Woo YS; Bahk WM; Jung YE; Jeong JH; Lee HB; Won SH; Lee KH; Jon DI; Yoon BH; Kim MD; Min KJ
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):418-24. PubMed ID: 24506520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay.
    Frye MA; Altshuler LL; Szuba MP; Finch NN; Mintz J
    J Clin Psychiatry; 1996 Jan; 57(1):17-21. PubMed ID: 8543542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tardive dyskinesia in patients receiving lithium maintenance therapy.
    Perényi A; Szücs R; Frecska E
    Biol Psychiatry; 1984 Nov; 19(11):1573-8. PubMed ID: 6151403
    [No Abstract]   [Full Text] [Related]  

  • 31. Lithium-neuroleptic neurotoxicity is dose dependent.
    Miller F; Menninger J
    J Clin Psychopharmacol; 1987 Apr; 7(2):89-91. PubMed ID: 2884238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gamma activity model for treatment-resistant bipolar psychotic mania.
    Kumar SR; Sinha VK; Tikka SK; Goyal N
    Indian J Pharmacol; 2015; 47(2):215-8. PubMed ID: 25878386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with pharmacologic noncompliance in patients with mania.
    Keck PE; McElroy SL; Strakowski SM; Stanton SP; Kizer DL; Balistreri TM; Bennett JA; Tugrul KC; West SA
    J Clin Psychiatry; 1996 Jul; 57(7):292-7. PubMed ID: 8666570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of neuroleptic dose and neurotoxicity in patients given lithium and a neuroleptic.
    Miller F; Menninger J
    Hosp Community Psychiatry; 1987 Nov; 38(11):1219-21. PubMed ID: 2889659
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjunctive clonazepam for maintenance treatment of bipolar affective disorder.
    Sachs GS; Rosenbaum JF; Jones L
    J Clin Psychopharmacol; 1990 Feb; 10(1):42-7. PubMed ID: 2106533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of the combination of lithium and neuroleptic drugs.
    Goldney RD; Spence ND
    Am J Psychiatry; 1986 Jul; 143(7):882-4. PubMed ID: 2872825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment.
    Charney DS; Kales A; Soldatos CR; Nelson JC
    Br J Psychiatry; 1979 Nov; 135():418-24. PubMed ID: 44211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptics and reserpine in refractory psychoses.
    Berlant JL
    J Clin Psychopharmacol; 1986 Jun; 6(3):180-4. PubMed ID: 2872238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of lithium in mania and maintenance therapy of bipolar disorder.
    Bowden CL
    J Clin Psychiatry; 2000; 61 Suppl 9():35-40. PubMed ID: 10826659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lithium augmentation in psychotic depression refractory to combined drug treatment.
    Nelson JC; Mazure CM
    Am J Psychiatry; 1986 Mar; 143(3):363-6. PubMed ID: 2869701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.